Merck CEO joins hunt for 'lots' of new drug deals

Merck CEO Ken Frazier

While many of its big rivals have been wheeling and dealing over the last few years, Merck has largely been quietly focused on absorbing Schering-Plough into its global system. But now Merck CEO Ken Frazier tells The Wall Street Journal that the Big Pharma giant plans to get busy making targeted deals. Lots of them. "As the CEO of Merck, I see my number one responsibility is to help drive the sustainability of R&D inside the company," he said. "And my hope is that we'll be able to complement what we are doing internally, with targeted deals on the outside to get the best of science, avoiding if we can a big merger and that will be my expectation and my goal." Story (sub. req.)